Penumbra (NYSE:PEN) this week posted fourth-quarter results that beat the revenue consensus on Wall Street but missed earnings estimates.
The Alameda, California-based company reported losses of -$24.6 million, or -66¢ per share, on sales of $204 million for the three months ended Dec. 31, 2021, for a sales growth of 22.24% compared with Q4 2020.
Get the full story on our sister site, Medical Tubing + Extrusion.